Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Randomised Single Centre Study to Compare the Long-Term Wear Characteristics of Marathon™ and Enduron™ Polyethylene Cup Liners in Primary Total Hip Replacement

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2009 by DePuy International.
Recruitment status was  Active, not recruiting
Information provided by:
DePuy International Identifier:
First received: September 13, 2005
Last updated: April 7, 2009
Last verified: April 2009

The purpose of this study is to compare the performance and compare the wear characteristics of two polyethylene cup liners, Marathon™ and Enduron™, in the treatment of patients with hip joint disease requiring a total hip replacement. Patients who enter the study will be randomly allocated to one of the polyethylene cup liners, Marathon™ or Enduron™ and will be evaluated at regular intervals using clinical and x-ray assessments.

Condition Intervention Phase
Post-Traumatic Arthritis
Collagen Disorders
Avascular Necrosis
Traumatic Femoral Fractures
Nonunion of Femoral Fractures
Congenital Hip Dysplasia
Slipped Capital Femoral Epiphysis
Device: Marathon™
Device: Enduron
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Randomised, Controlled, Single Centre, Blinded Study of the Wear Characteristics of Two Polyethylene Bearing Surfaces, Enduron vs. Marathon

Resource links provided by NLM:

Further study details as provided by DePuy International:

Primary Outcome Measures:
  • Evaluate the linear and volumetric wear at the three-year time point. [ Time Frame: 3yrs post surgery ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Demonstrate the difference in the 3D femoral head displacement between Enduron™ and Marathon™ three-years post-operatively [ Time Frame: 3yrs post-surgery ] [ Designated as safety issue: No ]
  • Merle D'Aubigne [ Time Frame: 5yrs and 10 yrs post-surgery ] [ Designated as safety issue: Yes ]
  • Harris Hip score [ Time Frame: 5yrs and 10 yrs post-surgery ] [ Designated as safety issue: No ]
  • Radiographic analysis [ Time Frame: 5yrs and 10yrs post-surgery ] [ Designated as safety issue: No ]

Enrollment: 119
Study Start Date: June 2001
Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Marathon™
Moderately cross-linked polyethylene liner in a modular acetabular component
Device: Marathon™
Moderately cross-linked polyethylene liner in a modular acetabular component
Active Comparator: Enduron™
Standard UHMWPE polyethylene liner in a modular acetabular component
Device: Enduron
Standard polyethylene liner in a modular acetabular component


Ages Eligible for Study:   45 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

i) Male or female subjects, aged between 45 and 75 years inclusive.

ii) Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained.

iii) Subjects who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.

iv) Subjects with non-inflammatory arthritis of the hip who require a primary hip arthroplasty and are considered by the Clinical Investigator to be suitable for a cemented femoral component and an uncemented acetabular component.

v) Subjects who have a Charnley A classification.

Exclusion Criteria:

i) Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.

ii) Women who are pregnant.

iii) Subjects who are known drug or alcohol abusers or with psychological disorders that could effect follow-up care or treatment outcomes.

iv) Subjects who have participated in a clinical study with an investigational product in the last month.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00208442

New Zealand
University Otago, Wellington Medical School of Medicine
Wellington, New Zealand
Sponsors and Collaborators
DePuy International
Study Director: Michael Borroff, B.Sc. M.Sc. DePuy International Ltd
  More Information

Responsible Party: Mick Borroff, DePuy International Ltd Identifier: NCT00208442     History of Changes
Other Study ID Numbers: CT99/31
Study First Received: September 13, 2005
Last Updated: April 7, 2009
Health Authority: New Zealand: Medicines and Medical Devices Safety Authority

Keywords provided by DePuy International:

Additional relevant MeSH terms:
Collagen Diseases
Femoral Fractures
Fractures, Bone
Hip Dislocation, Congenital
Slipped Capital Femoral Epiphyses
Bone Diseases
Bone Diseases, Developmental
Congenital Abnormalities
Connective Tissue Diseases
Epiphyses, Slipped
Joint Diseases
Leg Injuries
Musculoskeletal Abnormalities
Musculoskeletal Diseases
Rheumatic Diseases
Wounds and Injuries
Cardiovascular Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Therapeutic Uses processed this record on November 25, 2014